Study of HSK31858 for non-CF bronchiectasis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a body mass index (BMI) of at least 18.
- You have been diagnosed with bronchiectasis (not due to cystic fibrosis) with symptoms like chronic cough or phlegm.
- You have had at least 2 lung infections or flare-ups in the past year.
- You are not currently having a flare-up or needing treatment for one in the last 4 weeks.
- You do not have poorly controlled high blood pressure (systolic over 180 or diastolic over 110).
- You have not used certain other study drugs or medications that affect the study drug in the past few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This study tests a new medicine called galvokimig for adults with non-cystic fibrosis bronchiectasis, a condition where airways are damaged and cause chronic cough and sputum. The goal is to see if it reduces flare-ups and improves lung health.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.